Fiduciary Management Inc. WI Sells 252,521 Shares of Fresenius Medical Care AG (NYSE:FMS)

Fiduciary Management Inc. WI cut its stake in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) by 3.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,308,663 shares of the company's stock after selling 252,521 shares during the period. Fiduciary Management Inc. WI owned 1.08% of Fresenius Medical Care worth $142,828,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of FMS. Smartleaf Asset Management LLC boosted its stake in Fresenius Medical Care by 192.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company's stock worth $28,000 after buying an additional 806 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Fresenius Medical Care during the 3rd quarter valued at about $38,000. Russell Investments Group Ltd. grew its holdings in Fresenius Medical Care by 234.1% during the 4th quarter. Russell Investments Group Ltd. now owns 3,151 shares of the company's stock valued at $71,000 after purchasing an additional 2,208 shares during the last quarter. Jones Financial Companies Lllp raised its position in Fresenius Medical Care by 80.5% in the 4th quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company's stock worth $102,000 after purchasing an additional 2,012 shares during the period. Finally, Venturi Wealth Management LLC lifted its stake in Fresenius Medical Care by 8.4% in the fourth quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company's stock worth $129,000 after purchasing an additional 441 shares during the last quarter. 8.37% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on FMS. StockNews.com upgraded Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Truist Financial increased their target price on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a research note on Monday, January 6th.

Fresenius Medical Care Trading Up 2.0 %

Shares of Fresenius Medical Care stock traded up $0.48 on Thursday, hitting $24.12. 358,741 shares of the company traded hands, compared to its average volume of 324,238. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The company has a market cap of $14.15 billion, a PE ratio of 19.92, a PEG ratio of 0.76 and a beta of 0.93. The stock's 50 day moving average price is $23.92 and its 200-day moving average price is $22.94. Fresenius Medical Care AG has a 52 week low of $17.93 and a 52 week high of $25.96.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.